PPARGC1A and diabetic kidney disease: Indeed, the podocytes treated with a pharmacological SIRT1 agonist, both in vivo and in vitro, showed increased deacetylation and activation of PGC1α, which protected these cells against high-glucose-mediated mitochondrial injury and effectively mitigated the progression to diabetic kidney disease induced by oxidative stress [198].